Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
NCT00354042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2009-05-18
Summary
This study is designed to look at the safety aspects and effects of repeat inhaled doses of GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive Pulmonary Disease(COPD).
Conditions
Interventions
- DRUG
-
GW597901X
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials, MD, MSc, FPPM · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-08-31
More Related Trials
-
Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects
NCT00538057 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
NCT01387230 ·Status: COMPLETED ·Phase: PHASE3
-
A Healthy Volunteer Study With Inhaled GSK573719 and Placebo
NCT00803673 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 ·Status: COMPLETED ·Phase: PHASE2
-
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01316887 ·Status: COMPLETED ·Phase: PHASE3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837 ·Status: RECRUITING ·Phase: PHASE1
-
Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease
NCT00376714 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers
NCT01563042 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
NCT01039675 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
NCT00671216 ·Status: COMPLETED ·Phase: PHASE1
-
First Time in Human Study With GSK1325756
NCT01209052 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes
NCT03045887 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05037929 ·Status: COMPLETED ·Phase: PHASE2
-
Repeat Dose Study in Male Healthy Volunteer Smokers
NCT00615576 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
NCT00453687 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
NCT00862641 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
NCT00783003 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days
NCT00732472 ·Status: COMPLETED ·Phase: PHASE2
-
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics
NCT00364442 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00676052 ·Status: COMPLETED ·Phase: PHASE2
-
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
NCT01636713 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00929708 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT02130635 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers
NCT00475436 ·Status: COMPLETED ·Phase: PHASE1